Shanghai-based drug developer Allist Pharmaceuticals has raised RMB1.2 billion ($171 million) in a Series A round of funding led by Shiyu Capital. Other participants include Loyal Valley Capital and Suzhou Industrial Park Bioventure Investment.
Established in 2004, the company focuses on treatments for tumours and diabetes. It has launched two drugs so far - one for stomach diseases and the other for high blood pressure. It has a further eight...
US-based Liberty City Ventures has led a USD 359m round for Hong Kong blockchain media company Animoca Brands at a pre-money valuation of USD 5bn, more than double its valuation in October.
Harmay, a China-based omnichannel beauty products retailer, has raised USD 200m across Series C and D rounds.
Novotech, an Asia-based clinical trials specialist controlled by TPG Capital, has secured USD 760m in new equity and debt financing at a post-deal valuation of approximately USD 3bn.
Quadrant Private Equity has sold Journey Beyond, an Australia-based experiential tourism business, to US-based Hornblower Group, which is best known for offering cruise and sightseeing packages.